Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
269actual
Sites
95
Countries
Australia, Belgium, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-07 | actual | When the study began enrolling |
| Primary completion | 2025-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-10 | actual | The whole study's end, after follow-up |
| First posted | 2021-06-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Cervical Cancer
- SCCHN
- Pancreatic Cancer
- Esophageal SCC
- Metastatic Castration-resistant Prostate Cancer
- Triple Negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Epithelial Ovarian Cancer
- Endometrial Cancer
- Tissue Factor-Expressing Solid Tumors
Interventions
- Drug: XB002
- Drug: Nivolumab
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFDose-Escalation Stage: MTD/recommended dose for XB002
measured 18 months
Cohort-Expansion Stage: Objective Response Rate (ORR)
measured 12 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed